Short Interest in TScan Therapeutics, Inc. (NASDAQ:TCRX) Expands By 91.3%

TScan Therapeutics, Inc. (NASDAQ:TCRX) was the target of a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 419,700 shares, a growth of 91.3% from the March 31st total of 219,400 shares. Based on an average daily volume of 193,600 shares, the short-interest ratio is currently 2.2 days. Currently, 1.1% of the company’s shares are sold short.

Analyst Upgrades and Downgrades

Several research firms recently commented on TCRX. Wedbush reaffirmed an “outperform” rating and set a $10.00 target price on shares of TScan Therapeutics in a research note on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of TScan Therapeutics in a research note on Thursday, March 7th.

TScan Therapeutics Stock Up 0.4 %

NASDAQ:TCRX traded up $0.03 on Friday, hitting $7.32. The stock had a trading volume of 92,052 shares, compared to its average volume of 210,320. The business’s fifty day moving average is $7.19 and its 200 day moving average is $5.82. The company has a market cap of $350.50 million, a PE ratio of -3.87 and a beta of 0.90. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.18. TScan Therapeutics has a 52 week low of $1.62 and a 52 week high of $9.00.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings results on Wednesday, March 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.08. The business had revenue of $7.21 million for the quarter, compared to analyst estimates of $2.94 million. TScan Therapeutics had a negative return on equity of 60.65% and a negative net margin of 423.86%. On average, equities research analysts expect that TScan Therapeutics will post -1.03 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in TCRX. Letko Brosseau & Associates Inc. bought a new position in TScan Therapeutics in the third quarter worth approximately $83,000. Pale Fire Capital SE bought a new position in shares of TScan Therapeutics in the third quarter valued at approximately $42,000. abrdn plc bought a new position in shares of TScan Therapeutics in the fourth quarter valued at approximately $1,166,000. Finally, Cannon Global Investment Management LLC bought a new position in shares of TScan Therapeutics in the first quarter valued at approximately $139,000. Institutional investors own 82.83% of the company’s stock.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.